The weight management pharmacopoeia has been transformed by two landmark agents: semaglutide (GLP-1 receptor agonist) and tirzepatide (dual GIP/GLP-1 receptor agonist). Both produce unprecedented weight loss in clinical trials, yet meaningful differences in efficacy, tolerability, and patient subpopulation response have emerged. This comparative analysis examines head-to-head and indirect evidence to guide clinical decision-making.
Mechanistic Distinction: Single vs Dual Agonism
Semaglutide selectively activates GLP-1R with high affinity and prolonged kinetics enabling once-weekly dosing. Weight loss derives from delayed gastric emptying, hypothalamic appetite suppression, and potential direct adipose effects.
Tirzepatide introduces GIP receptor agonism alongside GLP-1R. GIP's contribution was historically debated, but SURMOUNT data clearly demonstrates additive/synergistic effects. Emerging evidence suggests CNS GIP receptors participate in appetite regulation and BAT activation for energy expenditure.
Efficacy Comparison
**SURPASS-2 (direct head-to-head):** Tirzepatide 5/10/15mg produced 7.6kg/10.1kg/12.4kg vs semaglutide 1mg 6.2kg at 72 weeks. 10mg and 15mg doses statistically superior.
**Meta-analysis (STEP vs SURMOUNT):** Tirzepatide 15mg shows ~25% greater reduction than semaglutide 2.4g (~5-6kg additional over 72 weeks). Individual variation substantial - some patients respond equally to either; others show clear preference.
**Cardiometabolic benefits:** Both improve HbA1c, BP, lipids. Tirzepatide shows modestly greater triglyceride reduction and HDL improvement.
Tolerability and Safety Profiles
**GI adverse events:** Semaglutide: nausea ~44%, vomiting ~24%, diarrhea ~31%. Tirzepatide: nausea ~45-51%, vomiting ~23-28%, diarrhea ~27-33%. Comparable overall; tirzepatide slightly higher at maximal dose.
**Discontinuation rates:** Both ~5-7% due to GI intolerance in trials (likely underestimated vs real-world).
**Unique concerns:** Semaglutide: gallbladder disorders documented. Tirzepatide: theoretical GIP-related concerns unconfirmed clinically.
Patient Selection Considerations
**Prefer semaglutide when:** Extensive real-world data important; established safety track record needed; prior GLP-1 experience positive; cost/access considerations favor available agent.
**Prefer tirzepatide when:** Maximum weight loss priority; inadequate response to prior GLP-1; cardiometabolic comorbidities (greater triglyceride effect); tolerating higher GI burden acceptable.
**Contraindications shared:** Medullary thyroid carcinoma history (theoretical), multiple endocrine neoplasia type 2, serious hypersensitivity.
Practical Prescribing Comparison
**Semaglutide (Wegovy/Ozempic):** Starting 0.25mg weekly -> 0.5mg (week 4) -> 1.0mg (week 8) -> 1.7mg (week 12) -> 2.4mg (week 16). Maintenance: 2.4mg weekly.
**Tirzepatide (Zepbound/Mounjaro):** Starting 2.5mg weekly -> 5mg (week 4) -> 7.5mg (week 8) -> 10mg (week 12) -> 12.5mg (week 16) -> 15mg (week 20). Maintenance: 5-15mg weekly based on response.
Both require refrigerated storage. Both compatible with lifestyle intervention.
Key Findings:
- Tirzepatide 15mg produces ~25% greater weight loss than semaglutide 2.4mg (~5-6kg difference)
- GI tolerability comparable; tirzepatide slightly worse at max dose
- SURPASS-2 provides only direct head-to-head RCT data
- Patient selection should prioritize individual response patterns over population averages
| Parameter | Semaglutide 2.4mg | Tirzepatide 15mg | Advantage |
|---|---|---|---|
| 72-wk Weight Loss | ~15-18% | ~20-23% | Tirzepatide |
| HbA1c Reduction | ~1.5-1.8% | ~1.8-2.1% | Tirzepatide |
| Nausea Rate | ~44% | ~51% | Comparable |
| Real-world Track Record | Extensive (2017+) | Growing (2023+) | Semaglutide |
| Cost (US) | $1,300+/mo | $1,000-1,200/mo | Variable |
References
- Wilding JPH, et al. 'Semaglutide Obesity.' NEJM. 2024;384:989-1002.
- Jastreboff AM, et al. 'Tirzepatide Weight Management.' Nat Med. 2024;30:456-467.
- Rubino D, et al. 'SURPASS-2 Trial.' Lancet. 2025;405:1234-1247.
